Metamark completes POC for prostate cancer test; FDA gives Fenwal good news on therapeutic plasma exchange protocol;

@FierceMedDev: Good news for battle-worn company? Olympus Gets Alliance Offers From Sony, Fujifilm, Terumo. Story | Follow @FierceMedDev

> Metamark Genetics has completed the proof-of-concept for its biomarker prognostic test for prostate cancer. The company is developing the test to see if it can help physicians determine whether a male's prostate cancer is slow-growing or aggressive, based on tumor tissue biopsy. Metamark release

> The FDA has cleared Fenwal to market a therapeutic plasma exchange protocol for the company's Amicus separator. Fenwal release

> If a person is aware of all aspects of his or her DNA, could he or she predict future health problems? Unfortunately, it appears as if the answer is no, according to a new study of twins. Story

> Researchers use neural imaging to help patients with a number of conditions, including epilepsy. Now, professor Ofer Levi and his research students from the University of Toronto's Institute of Biomaterials & Biomedical Engineering and The Edward S. Rogers Sr. Department of Electrical & Computer Engineering have developed a new cost-effective neural imaging system. News

> Canada's Biosign Technologies has inked a letter of intent to combine with EasyMed Services of Switzerland. Once the transaction is completed, the combined entity will continue to carry on the business of ESI. Biosign release

> Eisai's diagnostics subsidiary EIDIA has inked two agreements with medical equipment manufacturers Toshiba Medical Systems and GE Healthcare Japan. The agreement covers Japanese sales of PROTOCO2L, a carbon dioxide insufflation system for CT colonography, and carbon dioxide insufflation tube PROTOCO2L catheter set, both of which are currently marketed by EIDIA. Eisai release

And Finally... Researchers from Jackson Laboratory have shown that a single, targeted X-ray treatment of an individual eye in young, glaucoma-prone mice provided life-long and typically complete glaucoma protection. Release